ArticleMedical science monitor : international medical journal of experimental and clinical research2024
Prospective Analysis of Central Nervous System Infection Risks in Varicella-Zoster Virus Reactivation Cases: A Single-Center Prospective Study of 1030 Cases.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Lower lumbar and sacral herpes zoster with central nervous system complications: Two case reports.Dusunen adam : Bakirkoy Ruh ve Sinir Hastaliklari Hastanesi yayin organi · 2026Article
- Prognostic Factors and Clinical Characteristics of Varicella Zoster Virus Meningitis: Impact of Treatment Delay and Age-Related Differences in a Japanese Tertiary Hospital.Neurology international · 2026Article
- Varicella-zoster virus-associated central nervous system infection in immunocompromised vs. immunocompetent herpes zoster patients: a comparative study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND This study aimed to analyze the risk factors of central nervous system (CNS) infection caused by reactivation of varicella zoster virus (VZV) and provide reference for the prevention and early diagnosis of VZV-associated CNS infection. MATERIAL AND METHODS A prospective study was conducted on 1030 patients with acute herpes zoster (HZ) admitted to our hospital from January 2021 to June 2023. According to clinical manifestations and auxiliary examinations, they were divided into HZ group of 990 patients and VZV-associated CNS infection group of 40 patients. Differences in clinical characteristics and serum marker levels between the 2 groups were analyzed. RESULTS Compared with HZ group, the VZV-associated CNS infection group had a longer interval from onset to treatment, herpes mainly located in the head and neck, younger age, lower blood chloride and albumin levels, and higher levels of C-reactive protein and glutamyltranspeptidase (P<0.05, P<0.01). Logistic regression analysis found that prolonged interval from onset to treatment, herpes with craniocervical distribution, increased C-reactive protein, and decreased albumin content were independent risk factors for acute herpes zoster complicated with CNS infection (P<0.05). Combined with these 4 indicators to predict CNS infection, the AUC was 0.787, sensitivity was 64.5%, and specificity was 81.9%. CONCLUSIONS Identifying the risk factors for CNS infection caused by VZV reactivation is helpful for early screening. Clinicians should pay attention to acute HZ patients with delayed treatment, herpes occurring in the head and neck, elevated C-reactive protein levels, and decreased albumin levels. Early intervention can reduce the incidence of concurrent CNS infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.